treasure of the aztecs

treasure of the aztecs TORONTO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Onex Corporation (the “Company”) (TSX: ONEX) announced today the amendment of the terms of the Company’s ongoing substantial issuer bid (the “Offer”), pursuant to which the Company has offered to purchase from its shareholders (“Shareholders”), for cancellation, up to $400,000,000 of its subordinate voting shares (the “Subordinate Voting Shares”). All amounts in this press release are in Canadian dollars. The Offer has been amended to increase the price range offered to Shareholders who tender their Subordinate Voting Shares pursuant to the Offer to a price of not less than $108.00 per Subordinate Voting Share and not more than $117.00 per Subordinate Voting Share (in increments of $0.25 per Subordinate Voting Share) (the “New Range”). The New Range varies the original price range of the Offer of not less than $105.00 and not more than $112.00 per Subordinate Voting Share. In connection with the variation of the price range of the Offer, the expiry date of the Offer has been extended to 11:59 p.m. (Toronto time) on December 23, 2024 (the “Expiry Date”), unless further extended, varied or withdrawn by the Company. All other terms of the Offer remain unchanged. The Company anticipates announcing the results of the Offer by no later than December 27, 2024, following the close of markets. The Offer is for up to approximately 5% of the Company’s total number of issued and outstanding Subordinate Voting Shares (based on a purchase price equal to the minimum purchase price per Subordinate Voting Share and 73,973,642 Subordinate Voting Shares issued and outstanding as at the close of business on December 11, 2024). As a result of the variation of the Offer, any Shareholder who previously tendered their Subordinate Voting Shares to the Offer prior to the date hereof is advised that SUCH TENDER IS NO LONGER VALID and that the Shareholder WILL BE REQUIRED TO PROPERLY RETENDER THEIR SUBORDINATE VOTING SHARES in the manner described in the Notice of Variation (as defined below) in order to participate in the Offer. For greater certainty, any and all Subordinate Voting Shares previously tendered will be deemed to be withdrawn and will not be accepted for take-up and payment unless the Shareholder takes the additional steps described in the Notice of Variation. If you previously tendered your Subordinate Voting Shares and you do not properly retender your Subordinate Voting Shares in accordance with the procedures described in the Notice of Variation, your Subordinate Voting Shares will be returned to you by TSX Trust Company, the depositary for the Offer, promptly after the Expiry Date. For registered Shareholders who do not receive physical delivery of the Offer Documents by mail due to a postal disruption as a result of a Canada Post labour disruption or any other cause, the amended letter of transmittal (the “Amended Letter of Transmittal”) for use by registered Shareholders is available on SEDAR+ at www.sedarplus.ca and will also be posted on the Company’s website at www.onex.com . Registered Shareholders who wish to participate in the Offer should deliver a properly completed and duly executed Amended Letter of Transmittal (or a manually executed photocopy thereof) and any other documents required by the Amended Letter of Transmittal, to the Depositary at its address set forth on the Letter of Transmittal, prior to 11:59 p.m. (Toronto time) on the Expiry Date. A non-registered Shareholder who desires to deposit Subordinate Voting Shares under the Offer should immediately contact such Shareholder’s investment dealer, stock broker, commercial bank, trust company or other nominee in order to take the necessary steps to be able to deposit such Subordinate Voting Shares under the Offer. This press release is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction. The solicitation and the offer to buy the Subordinate Voting Shares will only be made pursuant to the offer to purchase and issuer bid circular dated November 8, 2024, as amended by the notice of variation and extension dated December 13, 2024 (the “Notice of Variation”), the Amended Letter of Transmittal and the amended notice of guaranteed delivery (collectively, the “Offer Documents”). Details of the Offer, including instructions for tendering Subordinate Voting Shares, are included in the Offer Documents. The Offer Documents will be mailed to shareholders, filed with applicable Canadian securities regulatory authorities and made available on SEDAR+ at www.sedarplus.ca , and will also be posted on the Company's website at www.onex.com . Shareholders should carefully read the Offer Documents prior to making a decision with respect to the Offer. ABOUT ONEX Onex invests and manages capital on behalf of its shareholders and clients across the globe. Formed in 1984, we have a long track record of creating value for our clients and shareholders. Our investors include a broad range of global clients, including public and private pension plans, sovereign wealth funds, insurance companies, family offices and high-net-worth individuals. In total, Onex has approximately $50 billion in assets under management, of which $8.5 billion is Onex’ own investing capital. With offices in Toronto, New York, New Jersey and London, Onex and its experienced management teams are collectively the largest investors across Onex’ platforms. Onex is listed on the Toronto Stock Exchange under the symbol ONEX. For more information on Onex, visit its website at www.onex.com . Onex’ security filings can also be accessed at www.sedarplus.ca . CAUTION REGARDING FORWARD LOOKING STATEMENTS This press release may contain, without limitation, statements concerning possible or assumed future operations, performance or results preceded by, followed by or that include words such as “believes”, “expects”, “potential”, “anticipates”, “estimates”, “intends”, “plans” and words of similar connotation, which would constitute forward-looking statements. Forward-looking statements are not guarantees. The reader should not place undue reliance on forward-looking statements and information because they involve significant and diverse risks and uncertainties that may cause actual operations, performance or results to be materially different from those indicated in these forward-looking statements. Except as may be required by Canadian securities law, Onex is under no obligation to update any forward-looking statements contained herein should material facts change due to new information, future events or other factors. These cautionary statements expressly qualify all forward-looking statements in this press release. FOR FURTHER INFORMATION:NEW YORK (AP) — The man charged with killing UnitedHealthcare CEO Brian Thompson was not a client of the medical insurer and may have targeted it because of its size and influence, a senior police official said Thursday. NYPD Chief of Detectives Joseph Kenny told NBC New York in an interview Thursday that investigators have uncovered evidence that Luigi Mangione had prior knowledge UnitedHealthcare was holding its annual investor conference in New York City. Mangione also mentioned the company in a note found in his possession when he was detained by police in Pennsylvania. “We have no indication that he was ever a client of United Healthcare, but he does make mention that it is the fifth largest corporation in America, which would make it the largest healthcare organization in America. So that’s possibly why he targeted that company,” said Kenny. UnitedHealthcare is in the top 20 largest U.S. companies by market capitalization but is not the fifth largest. It is the largest U.S. health insurer. Mangione remains jailed without bail in Pennsylvania, where he was arrested Monday after being spotted at a McDonald's in the city of Altoona, about 230 miles (about 370 kilometers) west of New York City. His lawyer there, Thomas Dickey, has said Mangione intends to plead not guilty. Dickey also said he has yet to see evidence decisively linking his client to the crime. Mangione's arrest came five days after the caught-on-camera killing of Thompson outside a Manhattan hotel. Police say the shooter waited outside the hotel, where the health insurer was holding its investor conference, early on the morning of Dec. 4. He approached Thompson from behind and shot him before fleeing on a bicycle through Central Park. Mangione is fighting attempts to extradite him back to New York so that he can face a murder charge in Thompson's killing. A hearing has been scheduled for Dec. 30. The 26-year-old, who police say was found with a “ ghost gun ” matching shell casings found at the site of the shooting, is charged in Pennsylvania with possession of an unlicensed firearm, forgery and providing false identification to police. Mangione is an Ivy League graduate from a prominent Maryland real estate family. In posts on social media, Mangione wrote about experiencing severe chronic back pain before undergoing a spinal fusion surgery in 2023. Afterward, he posted that the operation had been a success and that his pain had improved and mobility returned. He urged others to consider the same type of surgery. On Wednesday, police said investigators are looking at his writings about his health problems and his criticism of corporate America and the U.S. health care system . Kenny said in the NBC interview that Mangione's family reported him missing to San Francisco authorities in November.

Rising tech stocks pull Wall Street to another record By

Dallas Cowboys legend Troy Aikman has a rather surprising gut feeling about the future of coach Mike McCarthy. Aikman told TMZ Sports on Wednesday that his feeling is that the Cowboys will bring McCarthy back for 2025 despite their struggles this season. The former quarterback believes McCarthy is not fully to blame for the team’s 5-8 record, blaming “perplexing” decisions made by the front office during the offseason. “My gut tells me, right now, he will be back,” Aikman said . “That’s an assumption on my part, but that’s kind of what I’m feeling right now. “Mike McCarthy is a hell of a football coach, and he’s going to get other opportunities if in fact it’s not here in Dallas.” Aikman seemingly did not think this a few weeks ago, as he said during the Cowboys’ Week 11 “Monday Night Football” game that he was not confident that McCarthy would get a contract extension . The head coach is currently a lame duck, as his five-year contract expires at the end of the season. Jones made some comments about possibly keeping McCarthy following that game, so perhaps that changed Aikman’s mind. McCarthy’s reputation is still good in NFL circles, and his quarterback clearly wants him to return . That works in his favor. So does the fact that McCarthy put up three consecutive 12-win seasons for Dallas from 2021 through 2023. There is no ignoring the fact that the team is 5-8 this season, though, and that may weigh heavily on Jerry Jones’ mind when it comes time to make the decision. This article first appeared on Larry Brown Sports and was syndicated with permission.TOKYO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. MRM ("MEDIROM") announces that M3, Inc. (TOKYO PRIME: 2413), or an affiliate within the M3 group, is participating in the Series A equity financing round of MEDIROM MOTHER Labs Inc., a subsidiary of MEDIROM. NFES Technologies Inc. is the lead investor of the Series A financing round at a pre-money valuation of JPY9 billion. Additional information is available here: https://medirom.co.jp/en/ir/20240824/6148%09 Forward-Looking Statements Regarding MEDIROM Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about MEDIROM's possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as "may," "will," "should," "design," "target," "aim," "hope," "expect," "could," "intend," "plan," "anticipate," "estimate," "believe," "continue," "predict," "project," "potential," "goal," or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to MEDIROM's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause MEDIROM's actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond MEDIROM's control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects MEDIROM's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to MEDIROM's operations, results of operations, growth strategy and liquidity. More information on these risks and other potential factors that could affect MEDIROM's business, reputation, results of operations, financial condition, and stock price is included in MEDIROM's filings with the Securities and Exchange Commission (the "SEC"), including in the "Risk Factors" and "Operating and Financial Review and Prospects" sections of MEDIROM's most recently filed periodic report on Form 20-F and subsequent filings, which are available on the SEC website at www.sec.gov . MEDIROM assumes no obligation to update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ from those anticipated in these forward-looking statements, even if new information becomes available in the future. ABOUT M3, Inc. M3 is a one of a kind venture company that operates a multitude of global services centred around its physician platform such as m3.com. M3 is the first company incorporated after the year 2000 to be included in the Nikkei 225 Index. Its 330,000+ Japanese and 6,500,000+ global physician member panel serves as a central platform in advancing innovation and reform across healthcare worldwide. Tokyo Stock Exchange Prime Market (Securities code 2413) 1-11-44 Akasaka Minato-ku, Tokyo 107-0052 JAPAN Web https://corporate.m3.com/en ABOUT MEDIROM MOTHER Labs Inc. A subsidiary of MEDIROM Healthcare Technologies Inc. MRM , focuses on the health-tech sector. The company's core activities include the "Specific Health Guidance Program" offered through the "Lav" health application and development and sales of the 24/7 recharge-free MOTHER Bracelet smart tracker. By leveraging the features of the recharge-free MOTHER Bracelet, MOTHER Labs offers customizable health management solutions across diverse sectors, including caregiving, logistics, manufacturing, etc. MEDIROM Healthcare Technologies Inc. NASDAQ Symbol: MRM Tradepia Odaiba, 2-3-1 Daiba, Minato-ku, Tokyo, Japan Web https://medirom.co.jp/en Contact: ir@medirom.co.jp MEDIROM MOTHER Labs Inc. Tradepia Odaiba, 2-3-1 Daiba, Minato-ku, Tokyo, Japan MOTHER Bracelet is the world's first* 24/7 recharge-free smart tracker. It uses innovative technology from a Silicon Valley tech company that allows for power generation based on temperature differences between body and surrounding air. The recharge-free feature eliminates the risk of data loss when a device is taken off for recharge. MOTHER Bracelet records five basic metrics: heart rate, calories burned, body surface temperature, step count, and sleep. Official Website: https://mother-bracelet.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Right of Reply: Arik: Between facts and false narratives

Running back Nick Chubb says it is "important" that he returns for an eighth season with the Cleveland Browns after his current contract expires this spring. "I would say it's important. I started here. I'd like to finish here," Chubb said, per Dan Labbe of cleveland.com. "Cleveland just means a lot to me. Everything we've been through, ups and downs, but I'm proud to be drafted here." The report comes two days after Chubb told Cleveland fans he was "a Brown for life" during a charity event, per Denise Polverine Manoloff of Cleveland Magazine . Chubb, selected by the Browns in the second round of the 2018 draft, missed 21 straight regular-season games after suffering a severe knee injury in Week 2 of the 2023 campaign. The incident marked the second potentially career-ending left knee injury of Chubb's career. He also suffered a serious injury to the same knee while playing for Georgia in 2015. Chubb returned to the NFL field for the first time in over a year during the Browns' Week 7 loss to the Bengals. In seven starts since, he has recorded 93 carries for 291 yards and three touchdowns, adding five catches and a receiving touchdown. He is averaging 3.1 yards per carry, which would mark a full-season career-low and a significant departure from the 5.0 yards per attempt he recorded during his last full season in 2022. The Browns meanwhile head into Week 15 ranked 30th in the NFL in rushing offense. That lack of offense on the ground, combined with the team's struggles under center, led to Cleveland being eliminated from playoff contention in Week 14. Chubb played the 2024 season on a reworked deal with the Browns, which converted most of his original $11.75 base salary into incentives hinging on on offensive categories including playing time, receptions, rushing yards and rushing touchdowns. The Browns could consider offering Chubb a similarly incentive-laden contract in order to bring him back on a lower-risk deal in 2025.

Fianna Fail and Fine Gael eye independent TDs as option to secure Dail majorityAltcoins are influencing the direction of the cryptocurrency market and are no longer in the shadows. As we enter 2025, these innovative coins lead the charge, reimagining decentralized finance, smart contracts, and cross-border payments. But where do you even start when there are thousands of possibilities available? It takes strategy to choose which cryptocurrencies to invest in, regardless of your experience with cryptocurrency. In this list, we’ve rounded up the best altcoins to join by January 2025. Stellar (XLM), BlockDAG (BDAG), Chainlink (LINK), Avalanche (AVAX), and Ripple (XRP) are currently leading the field. Let’s examine the fundamental factors that make these coins the best available. 1. BlockDAG (BDAG): Crypto Made Smarter, Faster & Rewarding BlockDAG , an emerging layer-1 blockchain project, dominates the list of best altcoins to join in January 2025, with its successful ongoing presale raising over $172.5 million to become one of the most-talked-about new altcoin projects. BlockDAG in its batch 26 is priced at $0.0234, with early buyers witnessing an ROI of 2240%. Analysts predict that the coin could even reach $1 in 2025. Buyers are grabbing BDAG coins right now, taking advantage of the soon-ending BlockDAG bonuses starting from 250%. But what makes a coin still in its presale phase stand out in the crowded market? BlockDAG’s distinctive architecture, utilizing Directed Acyclic Graph (DAG) technology, offers quicker transactions, unmatched scalability, and lower costs compared to traditional blockchains. BlockDAG provides miners with an efficient, secure system that reduces energy consumption without sacrificing security. BlockDAG’s X-series miners with its user-friendly X1 mobile app and more advanced X10, X30, and X100 rigs, ensure an eco-friendly mining experience and is suitable for both seasoned miners and newbies as well. By addressing the gaps in existing crypto solutions, BlockDAG establishes itself as a solid choice for miners and buyers alike. Its promising ROI potential and unique functionality ensure that it is the best altcoin to join in January 2025. 2. Stellar (XLM): Simplifying Cross-border Payments Stellar (XLM) has recently formed partnerships with Paxos and Etherfuse, expanding its blockchain ecosystem. With features like fast transactions, low fees, multi-currency support, and a decentralized exchange, Stellar aims to enhance cross-border payments. Currently trading at approximately $0.3881, XLM has been earning recognition among leading crypto assets. Experts predict the coin may see a potential price increase in January 2025. The Stellar network draws notice for its efficient and inclusive financial solutions, positioning itself as one of the best altcoins to join in January 2025. 3. Chainlink (LINK): The Power of Decentralized Oracles Chainlink continues to push forward with collaborations like Banco Inter and Microsoft to enhance trade finance. The launch of its cross-chain interoperability protocol on zkSync highlights its commitment to innovation, even in a slow market. Chainlink’s major features include decentralized oracles, secure data feeds, and hybrid smart contracts, which bridge the gap between blockchain and real-world data. This alone places the coin to be one of the best altcoins to join in 2025. LINK’s is currently trading at around $24.82, while experts predict LINK could see further growth in 2025, due to its expanding adoption. 4. Avalanche (AVAX): Expanding Ecosystem & Partnerships Avalanche has made considerable progress with its recent updates, including the Avalanche9000 mainnet upgrade, reducing fees by over 90%, and securing $250 million in funding for its Layer-1 upgrade. The platform’s major features include high throughput, low latency, customizable subnets, and interoperability with Ethereum. AVAX is currently priced at approximately $40.95, and it might see growth in 2025 as its expanding ecosystem and partnerships are driving adoption across the DeFi and enterprise sectors. Avalanche’s growing adoption places it on the list of best altcoins to join in January 2025. 5. Ripple (XRP): The Bridge Currency for Global Financial Networks XRP has seen its fair share of fluctuations in the current volatile market, while it currently trends at around $2.29. Recent updates highlight regulatory optimism with the potential dropping of the SEC lawsuit, driving investor confidence in the coin. XRP’s major features include fast transaction speeds, low fees, and a unique consensus algorithm on the decentralized XRP Ledger. With scalability and cross-border payment solutions through RippleNet, XRP continues to be a strong choice for global financial institutions. Experts predict steady growth for XRP in 2025, making it one of the best altcoins to join in 2025. Ending Note While Stellar (XLM), Chainlink (LINK), Avalanche (AVAX), and Ripple (XRP) present promising prospects, BlockDAG (BDAG) distinguishes itself with its forward-thinking technology and environmentally conscious approach. Its innovative blockchain model enables rapid transaction speeds while addressing the pressing concerns of scalability and energy efficiency that continue to challenge the industry. With its ongoing presale that has raised over $172.5 million and its $600 million milestone well within its reach, BlockDAG is turning out to be the best new altcoin to buy in 2025 as it is expected to make a lasting impact throughout the year.

Salesforce, Inc. (CRM) Barclays 22nd Annual Global Technology Conference (Transcript)None

NoneNoneAssessing Alabama’s transfer portal class thus far

WiMi Hologram Cloud Inc. WIMI shares are trading higher on Thursday. The firm has announced the development of a Quantum Technology-Based Random Access Memory Architecture, known as QRAM. QRAM combines quantum logic gates such as the CNOT gate, V gate, and V+ gate to perform logical operations like AND, OR, NOT, and NOR within quantum systems, harnessing quantum properties like superposition and entanglement for enhanced computational efficiency. Unlike traditional RAM, which operates sequentially, QRAM leverages quantum superposition to enable parallel data access, significantly speeding up operations. Also Read: Azerbaijan Airliner Crash Kills 38: Weather, Russia Under Scrutiny Quantum entanglement further improves efficiency by allowing multiple qubits to be correlated without direct communication, resulting in faster data transfer and processing. This design dramatically enhances computational performance, especially for large-scale tasks like molecular simulations and complex optimizations. WiMi's QRAM architecture also integrates a quantum error correction mechanism, which ensures that qubit states remain stable and accurate during data read and write operations. This feature is crucial for maintaining reliability in quantum computing systems, where external disturbances can easily cause errors. The QRAM system is highly compatible with quantum processing units, enabling smooth data transmission between memory and processors, which optimizes overall computational efficiency. With its ability to handle large datasets, QRAM is poised to advance quantum machine learning and quantum encryption applications, providing faster training and secure data transmission. WiMi’s development of QRAM marks a significant step forward in quantum technology, setting the stage for a future where quantum computers play a crucial role in solving complex real-world problems. Price Action: WIMI shares are trading higher by 13.3% to $1.27 at last check Thursday. Also Read: SpaceX's Satellite Expansion Challenged: Ukrainian-Americans Allege Elon Musk's Russian Ties And Environmental Risks In FCC Petition © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Nazarbayev University Crisis: Shigeo Katsu Demands Audit TransparencyHow will the pharmaceuticals and healthcare industry change in 2025? One of the key advances in 2024 – artificial intelligence – is set to further disrupt healthcare into the new year. Digital Journal heard from Ryan Brown , Regional VP, Trial Landscape at H1 , a provider of global data on healthcare professionals, clinical insights, and research. Using AI to Combat Rare Diseases With nearly 1,000 AI-enabled devices approved , the U.S. FDA has strongly supported the use of AI in medicine. According to Brown: “In 2025, we will see AI leveraged for faster, more accurate diagnoses in rare disease cases, reducing the rate of more than a quarter of rare disease patients who spend 7+ years until they receive a correct diagnosis (up from 15 percent from 30 years ago). By connecting symptom patterns and medical histories across dispersed datasets, clinicians will identify rare conditions sooner, reducing the time to diagnosis by years and drastically improving outcomes.” Brown expands on the potentials of AI further: “Beyond diagnosis, AI will predict treatment responses, personalize therapies, and uncover new disease patterns. And, in rare diseases where patient populations are limited, AI’s ability to streamline trial design and identify patients most likely to benefit from specific therapies will further accelerate rare disease treatment.” Clinical Trial Diversity: Global Shift to Inclusive, Start-to-Finish Diversity in Clinical Trials In 2025, diversity will be a core consideration of clinical trial design from the outset, not just in later stages. Brown foresees: “Unlike the FDA’s guidance on diversity action plans, the U.K.’s draft Inclusion and Diversity Plan guidance pushes pharmaceutical companies to consider a wider range of factors beyond race and ethnicity, beginning at early-phase trials. This approach will influence global standards, and it won’t be long before the U.S. and other countries follow suit.” As to what is likely to happen: “This shift will push the industry to take a more granular approach to collecting and analyzing patient diversity data so trials reflect real-world populations from the start. For example, capturing detailed, region-specific nuances such as ethnic subgroups, transient populations, transgendered populations, religious sects, neurodiversity, rural populations, and other social determinants of health (SDoH).” Brown thinks: “This will stimulate advancements in clinical trial technology. AI and machine learning will be integral for capturing and analyzing this data to identify ideal trial candidates, and we’ll likely see new tools to track SDoH and applications that increase trial accessibility, especially for rural and underrepresented populations.” Novel Site Collaborations to Depoliticize Trial-Level DEI and Drive Culturally Compassionate Care With clinical trials,Brown predicts: “In the evolving landscape of clinical trials, the push for greater diversity, equity, and inclusion (DEI) has often been fraught with political undertones that can overshadow the genuine need for culturally compassionate care. Emerging models of site collaboration, however, are paving the way to reframe DEI beyond compliance mandates, fostering genuine, inclusive partnerships that resonate with the communities they aim to serve.” Brown adds: “By cultivating collaborations rooted in mutual respect and understanding, clinical trial sites are becoming hubs of inclusive health practices– reflected in their increasingly diverse workforce, ability to obtain novel data points from underserved communities to better inform AI models, and unique localized partnerships that support greater patient engagement. These novel approaches not only depoliticize DEI but also ensure that diverse populations receive care that reflects their unique cultural contexts, ultimately driving better trial outcomes and fostering trust within underrepresented communities.” Brown concludes: “This new era of site collaboration holds the promise of reimagining patient-centricity by focusing on what truly matters—health equity that transcends political divides, transforming trials into instruments of compassionate, culturally attuned care.” Dr. Tim Sandle is Digital Journal's Editor-at-Large for science news.Tim specializes in science, technology, environmental, business, and health journalism. He is additionally a practising microbiologist; and an author. He is also interested in history, politics and current affairs.

Data Center Colocation and Managed Hosting Services Market to Grow by USD 236.9 Billion (2023-2028), Report on AI-Driven Transformation - Technavio

Daily Post Nigeria Police detain man for slitting friend’s throat in Kogi Home News Politics Metro Entertainment Sport Metro Police detain man for slitting friend’s throat in Kogi Published on December 26, 2024 By Ochogwu Sunday A second-year undergraduate of Confluence University of Science and Technology, CUSTECH, Osara in Kogi, Usman Tijani, has been attacked and brutally injured by his friend, Abdulmuqeet Musari, Police have said. The Kogi Command’s Spokesman, SP Williams Aya, confirmed the incident and detention of the suspect by the command to NAN in Lokoja on Thursday. Aya said: “The suspect has been in our custody, and the investigation is ongoing. “He will be arraigned on completion of the investigation.” Narrating the incident in a statement, the Chairman, Adavi Local Government Area, LGA, Mr Bashiru Okatenwu, stated that the incident occurred at about 8 pm on December 23, around Adavi Burial Ground, New Zango in Adavi. According to the statement issued to NAN by Okatenwu’s Media Aide, Suleiman Acheneje, in Adavi, the victim is a 200-level student of the Department of Cyber Security in CUSTECH. “In the late hours of December 23, between 7 pm and 8 pm precisely, an unforeseen circumstance happened around Adavi Burial Ground, where a young boy, named Usman Tijani, got attacked by one of the bad eggs we still have in our society. “Usman was brutally injured by Abdulmuqeet Musari, whose intent was, no doubt, to kill him. “The victim was found nearly dead and rescued around 2 am in New Zango, Adavi LGA, where he was immediately rushed to Lokoja and has since been receiving treatment in a hospital there. “The culprit was already in the run but Kudos to the people’s Governor, the Chairman Of Adavi, and their Security intel, as they were able to apprehend the culprit in Ekiti,” Okatenwu said. He assured the good people of Adavi of his administration’s commitment to ensuring adequate security for their lives and property. Meanwhile, a relation of the victim, Zainab Avosuahu, who commented on the issue through her Meta, Facebook page post on Tuesday, said the suspect allegedly lured her nephew into the bush, collected N200,000 from him and slit his throat. Avosuahu stated: “The 19-year-old victim, who runs a POS business, is currently undergoing surgery in a Lokoja hospital. Related Topics: kogi police Don't Miss Police recover vehicle of kidnapped Anambra lawmaker You may like Police recover vehicle of kidnapped Anambra lawmaker Murder of retired Niger perm sec: Prime suspect dies in police custody Police arrest ex-convict for armed robbery two days after release from jail Police foil kidnap attempt in Katsina, rescue 10 hostages Imo police lose two officers, kill three kidnapping suspects Police enhance security measures for festive season in Taraba Advertise About Us Contact Us Privacy-Policy Terms Copyright © Daily Post Media Ltd

Bill Clinton discharged from hospital after 1-day staySMU has plenty to play for when it closes the regular season against California on Saturday afternoon in Dallas. The Mustangs (10-1, 7-0 Atlantic Coast Conference), who checked in at No. 9 in the latest College Football Playoff rankings on Tuesday, would like to send their seniors off the right way. They would also like to complete a perfect regular season before appearing in the ACC title game in their first year in the conference. Most importantly, they want to continue to strengthen their playoff case. "You've got the College Football Playoff, so every game matters. That's what's so cool about it now. The regular season is important," SMU coach Rhett Lashlee said. "We'd like to finish well in everything we do, particularly on Saturday, to finish off the regular season, continue our momentum into the following week. Hopefully, continue to show the committee and others that we're worthy of continuing to play this year." The Mustangs are a worthy playoff team to date. Kevin Jennings has established himself as one of the top quarterbacks in the country, throwing for 2,521 yards with 17 touchdowns and seven interceptions. He also has rushed for 315 yards and four TDs. Brashard Smith has been another standout, rushing for 1,089 yards and 13 TDs. Defensively, the Mustangs rank tied for 14th in the country with 20 takeaways. "Obviously they've had a phenomenal season," Cal coach Justin Wilcox said of SMU. "As soon as you turn the tape on, it doesn't take very long to see why their record is what it is. They're very, very good really in every phase of the game - extremely explosive and quick and fast. They've got a dominant D-line. We've got a lot of challenges in front of us and our guys are excited for that." Cal (6-5, 2-5) is coming off an emotional win, defeating rival Stanford 24-21 on Saturday to secure a bowl berth. The Golden Bears will appear in consecutive bowls for the first time since 2018-19 and are now looking to clinch their first winning season since 2019. SMU is not overlooking Cal, as all five of the Golden Bears' losses have come by one score. "You'd be hard-pressed to find a better 6-5 team in America," Lashlee said. "I think you can conservatively say they very, very easily could be 9-2." Cal is led by quarterback Fernando Mendoza, who has thrown for 3,004 yards with 16 touchdowns and six interceptions. Tight end Jack Endries leads the team with 555 yards receiving, while wide receiver Nyziah Hunter has caught a team-leading five touchdowns. Defensively, Cal has the ACC's top scoring defense (20.7 points per game) and is tied with Clemson for the ACC's best turnover margin (plus-13). Defensive back Nohl Williams is the star of the group -- he leads the country with seven interceptions. Even though oddsmakers are heavily favoring SMU, Cal is going into the game with a simple mindset. "Our task at hand is to make the best bowl game right now," Mendoza said. "And the way to do that is to go into Dallas, give it our best and ruin SMU's season." Saturday will mark the first conference meeting between these ACC newcomers, and just the second meeting between the programs all time. SMU won a 13-6 game back in 1957. --Field Level Media